The endocannabinoid system and emotional processing: Pathophysiology and therapeutic potential

Journal of Psychopharmacology

Volumn 26, Issue 1, 2012, Pages 3-6

  Finn, David P ^a   Viveros, Maria Paz ^b   Marco, Eva M ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS DERIVATIVE; CLOZAPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ENDOCANNABINOID; GLUCOCORTICOID; NABIXIMOLS; OLANZAPINE; RACLOPRIDE C 11; RIMONABANT; RISPERIDONE; VANILLOID RECEPTOR 1;

4 AMINOBUTYRIC ACID RELEASE; ADRENERGIC SYSTEM; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ANXIETY; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN REGION; CARDIOVASCULAR FUNCTION; CONCENTRATION (PARAMETERS); COPING BEHAVIOR; DEFENSIVE BEHAVIOR; DISEASE CONTROL; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG BINDING; DRUG DEPENDENCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECALL; DRUG TARGETING; DRUG TRANSPORT; EMOTION; EMOTIONALITY; ENERGY BALANCE; ENZYME INHIBITION; FEAR; FOOD INTAKE; GABAERGIC SYSTEM; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEART PROTECTION; HIPPOCAMPAL CA1 REGION; HOMEOSTASIS; HUMAN; IMMOBILIZATION STRESS; MENTAL DISEASE; NERVOUS SYSTEM FUNCTION; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPSYCHIATRY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPASTICITY; STRESS; THERAPY; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE; VASODILATATION;

ANIMALS; EMOTIONS; ENDOCANNABINOIDS; HUMANS; MENTAL DISORDERS; NEUROPSYCHIATRY;

EID: 84856456272     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111428526     Document Type: Review

References (49)

1. Agrawal A, Lynskey MT. Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction. 2009 ; 104: 518-532
2. Benyamina A, Kebir O, Blecha L, et al. CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addict Biol. 2011 ; 16: 1-6
3. Bermudez-Silva FJ, Cardinal P, Cota D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol. 2012 ; 26: 114-124
4. Bitencourt RM, Pamplona FA, Takahashi RN. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol. 2008 ; 18: 849-859
5. Butler RK, Ford GK, Hogan M, et al. Fear-induced suppression of nociceptive behaviour and activation of Akt signalling in the rat periaqueductal grey: role of fatty acid amide hydrolase. J Psychopharmacol. 2012 ; 26: 83-91
6. Casadio P, Fernandes C, Murray RM, et al. Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev. 2011 ; 35: 1779-1787
7. Chhatwal JP, Davis M, Maguschak KA, et al. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology. 2005 ; 30: 516-524 (Pubitemid 40271154)
8. Clapper JR, Moreno-Sanz G, Russo R, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci. 2010 ; 13: 1265-1270
9. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Front Horm Res. 2008 ; 36: 135-145
10. Cota D, Sandoval DA, Olivieri M, Prodi E, D'alessio DA, Woods SC, et al. Food intake-independent effects of Cb1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring). 2009 ; 17: 1641-1645
11. Di Marzo V, Despres JP. CB1 antagonists for obesity-what lessons have we learned from rimonabant?. Nat Rev Endocrinol. 2009 ; 5: 633-638
12. Finn DP. Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiology. 2010 ; 215: 629-646
13. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964 ; 86: 1646-1647
14. 1A receptors. J Psychopharmacol. 2012 ; 26: 104-113
15. Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry. 2007 ; 20: 393-397 (Pubitemid 46889667)
16. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009 ; 374: 1383-1391
17. Haughey HM, Marshall E, Schacht JP, et al. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction. 2008 ; 103: 1678-1686
18. Hiley CR. Endocannabinoids and the heart. J Cardiovasc Pharmacol. 2009 ; 53: 267-276
19. Horder J, Browning M, Di Simplicio M, et al. Effects of 7 days treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol. 2012 ; 26: 125-132
20. Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev. 2008 ; 1: 114-123
21. Lopez-Moreno JA, Echeverry-Alzate V, Buhler KM. The genetic basis of the endocannabinoid system and drug addiction in humans. J Psychopharmacol. 2012 ; 26: 133-143
22. Machielsen M, Scheltema Beduin A, Dekker N, et al. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol. 2012 ; 26: 189-195
23. Marco EM, Laviola G. The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives. J Psychopharmacol. 2012 ; 26: 150-163
24. Marco EM, Adriani W, Llorente R, et al. Detrimental psychophysiological effects of early maternal deprivation in adolescent and adult rodents: altered responses to cannabinoid exposure. Neurosci Biobehav Rev. 2009 ; 33: 498-507
25. Minkkila A, Saario S, Nevalainen T. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors. Curr Top Med Chem. 2010 ; 10: 828-858
26. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol. 2008 ; 13: 196-212 (Pubitemid 351698889)
27. Moreira FA, Aguiar DC, Resstel LB, et al. Neuroanatomical substrates involved in cannabinoid modulation of defensive responses. J Psychopharmacol. 2012 ; 26: 40-55
28. Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol. 2009 ; 88: 335-369
29. Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci. 2006 ; 1074: 514-536 (Pubitemid 44532857)
30. Onaivi ES, Ishiguro H, Gu S, et al. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol. 2012 ; 26: 92-103
31. O'Sullivan SE, Kendall DA, Randall MD. Time-dependent vascular effects of endocannabinoids mediated by Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma). PPAR Res. 2009 ; 2009: 425289
32. O'Sullivan SE, Kendall PJ, Kendall DA. Endocannabinoids and the cardiovascular response to stress. J Psychopharmacol. 2012 ; 26: 71-82
33. Pacher P, Mukhopadhyay P, Mohanraj R, et al. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension. 2008 ; 52: 601-607
34. Pamplona FA, Takahashi RN. Psychopharmacology of the endocannabinoids: far beyond anandamide. J Psychopharmacol. 2012 ; 26: 7-22
35. Pamplona FA, Bitencourt RM, Takahashi RN. Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiol Learn Mem. 2008 ; 90: 290-293
36. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs. 2010 ; 11: 51-62
37. Randall MD, Kendall DA, O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol. 2004 ; 142: 20-26 (Pubitemid 38698188)
38. Roche M, Finn DP. Brain CB2 receptors: implications for neuropsychiatric disorders. Pharmaceuticals. 2010 ; 3: 2517-2553
39. Rubino T, Zamberletti E, Parolaro D. Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol. 2012 ; 26: 177-188
40. Ruehle S, Aparisi Rey A, Remmers F, et al. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol. 2012 ; 26: 23-39
41. Schacht JP, Selling RE, Hutchison KE. Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis. Psychopharmacology (Berl). 2009 ; 203: 511-517
42. 3 receptor availability. J Psychopharmacol. 2012 ; 26: 144-149
43. Suarez J, Bermudez-Silva FJ, Mackie K, et al. Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol. 2008 ; 509: 400-421
44. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005 ; 310: 329-332 (Pubitemid 41457202)
45. Viveros MP, Llorente R, Moreno E, et al. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav Pharmacol. 2005a ; 16: 353-362 (Pubitemid 41404806)
46. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005b ; 81: 331-342 (Pubitemid 40807131)
47. Viveros MP, Llorente R, Suarez J, et al. The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. J Psychopharmacol. 2012 ; 26: 164-176
48. Wang M, Hill MN, Zhang L, et al. Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation. J Psychopharmacol. 2012 ; 26: 56-70
49. Xi ZX, Peng XQ, Li X, et al. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci. 2011 ; 14: 1160-1166